Developing vaccines to activate broadly neutralizing antibodies against HIV-1
Investigation into the activation of multiple bnAb precursors using structure-designed immunogens and Ig knock-in mice
['FUNDING_R01'] · WISTAR INSTITUTE · NIH-10974029
This study is looking at new ways to create vaccines that help the immune system fight HIV-1 by encouraging it to produce a wide range of protective antibodies, using special mice to test how well these vaccines work.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WISTAR INSTITUTE (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10974029 on ClinicalTrials.gov |
What this research studies
This research focuses on creating vaccines that can stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV-1. It employs advanced protein engineering techniques and utilizes specially designed mice that carry human-like antibodies to test the effectiveness of these vaccines. The goal is to explore a dual lineage targeting approach to enhance the immune response and improve the breadth of neutralization against the virus. By understanding how to activate different antibody lineages, the research aims to pave the way for more effective HIV-1 vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at risk for HIV-1 infection or those living with HIV who are interested in new vaccine approaches.
Not a fit: Patients who are not at risk for HIV-1 or those who are already effectively managing their HIV with current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV-1 vaccine that provides broader protection against the virus.
How similar studies have performed: Other research has shown promise in activating bnAbs through sequential immunization strategies, but this dual lineage approach is relatively novel.
Where this research is happening
PHILADELPHIA, UNITED STATES
- WISTAR INSTITUTE — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ESCOLANO, AMELIA — WISTAR INSTITUTE
- Study coordinator: ESCOLANO, AMELIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus